Surface Oncology Inc

NASDAQ:SURF   3:59:44 PM EDT
7.91
+0.55 (+7.47%)
Products

Surface Oncology’s SRF617 Receives Orphan Drug Designation From FDA For Treatment Of Pancreatic Cancer

Published: 03/30/2021 20:47 GMT
Surface Oncology Inc (SURF) - Surface Oncology’s Srf617 Receives Orphan Drug Designation From FDA for Treatment of Pancreatic Cancer.